CD20 Inhibitor

MIL62 (FUT8-KO) is a CD20-targeting antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody.

MEDI-552 is a human IgG monoclonal antibody targeting CD20/membrane-spanning 4-domains subfamily A member 1 (MS4A1).

NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a K_d of 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma.

MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL).

SM09 is an anti-human CD20 antibody.

Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.

TG20 is an anti-CD20 monoclonal antibody that binds to a specific discontinuous epitope on CD20 with a K_d of 10–20 nM. TG20 exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). TG20 also enhances complement-dependent cytotoxicity (CDC) activity. TG20 can be used in research on B-cell lymphomas .

PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma.

PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20.

BVX20 is a human monoclonal antibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL.